Vaxart Inc. (VXRT) News

Vaxart Inc. (VXRT): $3.53

0.37 (+11.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VXRT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter VXRT News Items

VXRT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VXRT News Highlights

  • VXRT's 30 day story count now stands at 16.
  • Over the past 27 days, the trend for VXRT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • BEAT, CORT and FOLD are the most mentioned tickers in articles about VXRT.

Latest VXRT News From Around the Web

Below are the latest news stories about Vaxart Inc that investors may wish to consider to help them evaluate VXRT as an investment opportunity.

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 25, 2022

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the fourth quarter and full year 2021, reporting forward mom

Yahoo | February 24, 2022

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- A new study p

Yahoo | February 24, 2022

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

Right now, I'm thinking of a biotech company with game-changing vaccine technology and a company whose successes are tied to the cryptocurrency market. The coronavirus pandemic put Vaxart's (NASDAQ: VXRT) name on the map. Vaxart's candidate still is in phase 2 trials.

Yahoo | February 23, 2022

Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

Yahoo | February 16, 2022

Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

Yahoo | February 16, 2022

Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates

Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutic

Yahoo | February 14, 2022

Is Vaxart Stock a Buy Now?

On the other hand, picking a stock others have largely abandoned could yield impressive returns if the company manages to get back in the good graces of investors. With that in mind, let's look at a biotech company whose shares have been pummeled lately: Vaxart (NASDAQ: VXRT). Vaxart takes a different approach to vaccination: The company focuses on developing oral vaccines.

Yahoo | February 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6566 seconds.